Effect of first‑month specific therapy determines long‑term clinical outcome in patients with pulmonary arterial hypertension
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Efficacy of pulmonary arterial hypertension (PAH)-specific therapy may differ among the patients depending on the PAH aetiology. Aim: To compare the real‐life efficacy of PAH‐specific therapy between non‐congenital heart disease (non‐CHD) and CHD groups of PAH patients and to determine whether an early clinical response has an impact on prognosis. Methods: Clinical data from 41 PAH patients, 21 non‐CHD and 20 CHD patients, were included in the study. The WHO functional class (WHO‐FC), 6‐minute walk dis-tance (6MWD) and NT‐proBNP serum level were compared at baseline and after 1 and 7 months of PAH‐specific treatment. Only patients with unmodified PAH‐specific therapy during 7‐month follow‐up were enrolled in the study. Results: Baseline characteristics revealed higher WHO‐FC and increased [log e ]NT‐proBNP levels (7.74 ±1.05 vs 6.51 ±1.48; p = 0.008) in non‐CHD vs. CHD patients; baseline 6MWD was similar in both groups (283.3 ±148.5 m vs 339.2 ±114.7 m). Clinical improvement by at least one WHO‐FC after 1‐month treatment was observed more frequently in non‐CHD (55%) when compared with CHD patients (25%, p = 0.04) and was comparable (50% vs 50%) after 7‐month observation. Non‐CHD patients, who did not improve within 1 month of treatment were unlikely to achieve improvement after 7 months. The 6MWD increased during the first month of treatment in non‐CHD (p=0.009) and in CHD patients (p=0.006) when compared to baseline values and remained at this level after 7 months of treatment. [Log e ]NT‐proBNP levels markedly declined only in non‐CHD patients, who had an improvement in WHO‐FC (8.0 ±1.0 vs 7.4 ±1.1, p = 0.04) in the first month. In CHD patients, the decrease in [log e ]NT‐proBNP level was seen (6.5 ± 1.5 vs 6.1 ±1.5, p = 0.04) only within a 1‐month observation. Conclusion: Efficacy of 1‐month PAH‐specific therapy is aetiology‐dependent and determines clinical outcome in patients with PAH. JRCD 2018; 3 (6): 198–203.
Authors and Affiliations
Adrianna Nowak, Karolina Bula, Karol Głowacki, Wojciech Gawin, Konstantinos Nechoritis, Marek Grabka, Katarzyna Mizia‐Stec
Keywords
Related Articles
- EP ID EP286458
- DOI 10.20418/jrcd.v3i6.316.g223
- Views 88
- Downloads 0
Exercise capacity in adult patients after Fontan procedure. (RCD code: IV-5B.1)
Background: The aim of Fontan procedure is to restore a balance between pulmonary and systemic circulation and improve or nearly normalize arterial saturation in patients with functionally univentricular heart. Neverthel...
The pilot study of role of electrical cardiometry in non‑invasive assessment of hemodynamic parameters in patients with pulmonary arterial hypertension (RCD code: II‑1A.1)
Background: Electrical cardiometry (EC) technique could estimate cardiac output (CO), cardiac index (CI) and other parameters related to cardiac contractility and fluid status by measuring the thoracic electrical bioimpe...
Highlights from EuroEcho-Imaging 2016 Congress of the European Society of Cardiology, Leipzig, Germany.
EuroEcho-Imaging is the annual meeting of the European Association of Cardiovascular Imaging (EACVI), that attracts participants from all over the world with all modalities of cardiovascular non-invasive imaging. This ti...
Pulmonary arterial hypertension: management in specific medical conditions
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Due to the narrowing of the blood vessels in the lungs, pul- monary vascular resistance and pulmonary pressures increase. This results in reduced...
A 23‑year‑old woman with Marfan syndrome and spine deformity (RCD code: I-2A.1)
Marfan syndrome is one of the most common heritable connective tissue disorders that is caused by various mutations of the Fibrillin-1(FBN1) gene. The cardinal features of Marfan syndrome are aortic root dilatation and e...